The population of Americans who spend more than $50,000 per year on prescription drugs grew 63% in 2014, largely driven by hepatitis C and cancer therapies, according to an Express Scripts report.
The population of Americans who spend more than $50,000 per year on prescription drugs grew 63% in 2014, largely driven by hepatitis C and cancer therapies, according to a report from Express Scripts.
The number of patients in the analysis receiving medication treatment for hepatitis C jumped 733% in 2014.
Related:Oncology drug spending soars
Dr StettinThese figures further support the need for a national dialog about fair and sustainable drug pricing in the United States, according to Glen Stettin, MD, Express Scripts senior vice president, clinical, research and new solutions.
“The profile emerging from this research shows these patients are overwhelmingly taking specialty medications, and have multiple comorbidities, prescriptions and prescribers,” said Glen Stettin, MD, senior vice president, clinical, research and new solutions, at Express Scripts. “These insights highlight clear opportunities for payers to work with their PBM to improve care, quality of life and health outcomes for the patients who rely on these costly, complex therapies.”
The report also found:
NEXT: Recommendations for formulary managers
The analysis examined de-identified prescription drug claims of 31.5 million insured Americans between 2013 and 2014. The research included beneficiaries with pharmacy coverage through commercial insurers, Medicare and Medicaid.
Related:States blame hep C cases for increased opioid abuse
Based on this report Dr Stettin offers 3 recommendations for formulary managers:
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More
Trump Impact on Medicare Drug Price Negotiations Uncertain
Published: January 22nd 2025 | Updated: January 22nd 2025Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Read More